Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.

Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.

But the overall survival benefit in prostate cancer is still driven by HRR mutations.

Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.

Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.

The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.

Two masked bispecific antibodies, licensed for $100m, produce promising early data.

The company impresses investors, but money’s running short.

The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.